

Anti-C5 (Eculizumab), Humanized Antibody

rev 01/21

CATALOG NO.: A2138-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant humanized IgG2/4 kappa monoclonal antibody that inhibits the cleavage of C5 into C5a and C5b by C5 convertases. Inhibition of C5 cleavage prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 have proinflammatory and prothrombic properties and play a significant role in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The original monoclonal antibody received FDA approval for the treatment of PNH and aHUS. This monoclonal antibody also received approval to treat adults suffering from general Myasthenia Gravis (gMG) but are anti-AChR antibody-positive.

ALTERNATE NAMES: C5D, C5a, C5b, ECLZB, CPAMD4, C5, Complement C5

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant / IgG2/4, kappa

SOURCE: CHO cells

IMMUNOGEN: Eculizumab

CAS NUMBER: 219685-50-4

MOLECULAR WEIGHT: 148 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at 80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-CTLA-4 (Ipilimumab), humanized Antibody (A2110)
 Anti-TNF- α (Adalimumab), humanized Antibody (A1048)
 Anti-RSV (Felvizumab), Human IgG1 Antibody (A1446)
 Anti-EGFR (Panitumumab), Humanized Antibody (A1050)
 Anti-Flavivirus group antigen, Human IgG1 Antibody (A1102)

FOR RESEARCH USE ONLY! Not to be used on humans.